+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PARP Inhibitor Biomarkers Market Size, Share & Trends Analysis Report By Product (Kits, Assays), By Services (BRCA 1&2 Testing, HRD Testing), By Application, By Region, And Segment Forecasts, 2024 - 2030

  • PDF Icon

    Report

  • 100 Pages
  • April 2024
  • Region: Global
  • Grand View Research
  • ID: 5967400
Description Jump to:

PARP Inhibitor Biomarkers Market Growth & Trends

The global PARP inhibitor biomarkers market size is anticipated to reach USD 1.60 billion by 2030 and is projected to grow at a CAGR of 8.54% from 2024 to 2030. The rising incidence of breast cancer is a significant factor for market expansion in the PARP Inhibitors biomarkers sector. According to the WHO article published in 2022, increasing prevalence of cancer cases, with an estimated 20 million new cases of 9.7 million deaths reported. Despite advancements, the fight against cancer remains tough, with an estimated 53.5 million individuals surviving within 5 years of diagnosis. Moreover, Female breast cancer emerges as a significant concern, ranking second in global cases at 2.3 million (11.6%), accounting for 670,000 deaths (6.9%). Especially it stands as the most widespread among women across 157 out of 185 countries surveyed.

Advancements in genomic technologies have significantly contributed to developing and refining PARP inhibitor biomarkers. According to the NCBI article published in August 2021, these advancements have enabled researchers to identify and validate biomarkers that predict patients' response to PARP inhibitors, thereby facilitating personalized treatment strategies. A study developed a 3D functional assay to identify biomarkers predictive of the response to poly-ADP ribose polymerase inhibitors (PARPis) in high-grade serous ovarian cancer (HGSOC) patients. This approach allowed for a more accurate and comprehensive understanding of how cells respond to PARP inhibitors in a physiologically relevant environment.

The increasing expenditure for treatment and management fuels the market growth. According to the articleBioMed Central Ltd published in September 2022, particularly for breast and ovarian cancer, is a major issue influenced by several factors, including the stage of diagnosis, the specific treatments used, and the overall healthcare costs associated with cancer care. The provided sources offer insights into the financial burden of treatments and the factors contributing to their rising expenditure. Breast and ovarian cancer patients face significant financial burdens throughout their treatment journey.

The financial burden of oncology care can be significant and vary widely based on diagnosis stage and treatment methods. Patients diagnosed in later stages generally incur higher annual and cumulative healthcare expenses compared to those diagnosed earlier. This trend is evident in the data, showing notably higher mean annual and cumulative healthcare costs for patients diagnosed at later stages. The considerable rise in cumulative costs, particularly for stage IV diagnoses across various cancer types such as ovarian, emphasizes the critical importance of early detection. Timely diagnosis allows more effective treatment and also contributes to better patient outcomes and reduced healthcare expenditures further propelling market growth.

PARP Inhibitor Biomarkers Market Report Highlights

  • The kits segment led the market with the largest revenue share of 65.35% in 2023. It is due to attributed of rising the awareness regarding effective diagnostics solutions
  • The assays segment is anticipated to grow at the fastest CAGR during the forecast period, owing to being a crucial component for developing and validating PARP inhibitor biomarkers, enabling researchers and clinicians to measure these biomarkers' levels in biological samples accurately
  • Based on services, the BRCA1 & 2 testing segment led the market with the largest revenue share of 43.54% in 2023, due to its critical role in treatment. The rise in importance of PARP inhibitors for BRCA1 and BRCA2 mutation-associated cancers has further boosted its significance
  • In terms of application, the breast cancer segment led the market with the largest revenue share of 48.42% in 2023. The ovarian cancer segment is anticipated to grow at the fastest CAGR during the forecast period
  • North America dominated the market with the revenue share of 43.95% in 2023, owing to factors such as advancement in genomic technologies, high purchasing power parity, government support for quality healthcare, and funding for development of novel diagnostics

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Services
1.2.3. Application
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal Database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Services outlook
2.2.3. Application outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. PARP Inhibitor Biomarkers Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of breast cancer
3.2.1.2. Advancements in genomic technologies
3.2.1.3. Rising expenditure for cancer treatment
3.2.1.4. Growing adoption of personalized medicine and precision therapy
3.2.2. Market restraint analysis
3.2.2.1. High cost of PARP inhibitor biomarker test kits and assays
3.2.2.2. Limited awareness and understanding of PARP inhibitors biomarkers
3.3. PARP Inhibitor Biomarkers Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.2. PESTEL Analysis
Chapter 4. PARP Inhibitor Biomarkers Market: Product Estimates & Trend Analysis
4.1. PARP Inhibitor Biomarkers Market: Product Dashboard
4.2. PARP Inhibitor Biomarkers Market: Product Movement Analysis
4.3. PARP Inhibitor Biomarkers Market by Product Revenue
4.4. Kits
4.4.1. Kits Market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Assays
4.5.1. Assays Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. PARP Inhibitor Biomarkers Market: Services Estimates & Trend Analysis
5.1. PARP Inhibitor Biomarkers Market: Services Dashboard
5.2. PARP Inhibitor Biomarkers Market: Services Movement Analysis
5.3. PARP Inhibitor Biomarkers Market by Services Revenue
5.4. BRCA 1 & 2 Testing
5.4.1. BRCA 1 & 2 Testing Market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. HRD Testing
5.5.1. HRD Testing Market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. HRR Testing
5.6.1. HRR Testing Market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Others
5.7.1. Others Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. PARP Inhibitor Biomarkers Market: Application Estimates & Trend Analysis
6.1. PARP Inhibitor Biomarkers Market: Application Dashboard
6.2. PARP Inhibitor Biomarkers Market: Application Movement Analysis
6.3. PARP Inhibitor Biomarkers Market by Application Revenue
6.4. Breast Cancer
6.4.1. Breast Cancer Market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Ovarian Cancer
6.5.1. Ovarian Cancer Market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Others
6.6.1. Others Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. PARP Inhibitor Biomarkers Market: Regional Estimates & Trend Analysis
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. North America
7.3.2. U.S.
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework
7.3.2.3. Competitive scenario
7.3.2.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
7.3.3. Canada
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework
7.3.3.3. Competitive scenario
7.3.3.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. Europe
7.4.2. UK
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework
7.4.2.3. Competitive scenario
7.4.2.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.3. Germany
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework
7.4.3.3. Competitive scenario
7.4.3.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.4. France
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework
7.4.4.3. Competitive scenario
7.4.4.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.5. Italy
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework
7.4.5.3. Competitive scenario
7.4.5.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.6. Spain
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework
7.4.6.3. Competitive scenario
7.4.6.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.7. Norway
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework
7.4.7.3. Competitive scenario
7.4.7.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.8. Sweden
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework
7.4.8.3. Competitive scenario
7.4.8.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.9. Denmark
7.4.9.1. Key country dynamics
7.4.9.2. Regulatory framework
7.4.9.3. Competitive scenario
7.4.9.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Asia Pacific
7.5.2. Japan
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework
7.5.2.3. Competitive scenario
7.5.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.3. China
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework
7.5.3.3. Competitive scenario
7.5.3.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.4. India
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework
7.5.4.3. Competitive scenario
7.5.4.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.5. Australia
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework
7.5.5.3. Competitive scenario
7.5.5.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.6. South Korea
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework
7.5.6.3. Competitive scenario
7.5.6.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.7. Thailand
7.5.7.1. Key country dynamics
7.5.7.2. Regulatory framework
7.5.7.3. Competitive scenario
7.5.7.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Latin America
7.6.2. Brazil
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework
7.6.2.3. Competitive scenario
7.6.2.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.3. Mexico
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework
7.6.3.3. Competitive scenario
7.6.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.4. Argentina
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework
7.6.4.3. Competitive scenario
7.6.4.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. MEA
7.7.2. South Africa
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework
7.7.2.3. Competitive scenario
7.7.2.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.3. Saudi Arabia
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework
7.7.3.3. Competitive scenario
7.7.3.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.4. UAE
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework
7.7.4.3. Competitive scenario
7.7.4.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.5. Kuwait
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework
7.7.5.3. Competitive scenario
7.7.5.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Myriad Genetics, Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Ambry Genetics
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Thermo Fisher Scientific Inc.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Illumina, Inc.
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. CENTOGENE N.V.
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Amoy Diagnostics Co., Ltd.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Invitae Corporation
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. NeoGenomics Laboratories.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. QIAGEN
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Agilent Technologies, Inc.
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America PARP inhibitor biomarkers market, by region, 2018 - 2030 (USD Million)
Table 3 North America PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 4 North America PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 5 North America PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 6 U.S. PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 7 U.S. PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 8 U.S. PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 9 Canada PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 10 Canada PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 11 Canada PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 12 Europe PARP inhibitor biomarkers market, by region, 2018 - 2030 (USD Million)
Table 13 Europe PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 14 Europe PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 15 Europe PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 16 Germany PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 17 Germany PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 18 Germany PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 19 UK PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 20 UK PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 21 UK PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 22 France PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 23 France PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 24 France PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 25 Italy PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 26 Italy PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 27 Italy PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 28 Spain PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 29 Spain PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 30 Spain PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 31 Denmark PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 32 Denmark PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 33 Denmark PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 34 Sweden PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 35 Sweden PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 36 Sweden PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 37 Norway PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 38 Norway PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 39 Norway PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 40 Asia Pacific PARP inhibitor biomarkers market, by region, 2018 - 2030 (USD Million)
Table 41 Asia Pacific PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 42 Asia Pacific PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 43 Asia Pacific PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 44 China PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 45 China PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 46 China PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 47 Japan PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 48 Japan PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 49 Japan PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 50 India PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 51 India PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 52 India PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 53 South Korea PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 54 South Korea PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 55 South Korea PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 56 Australia PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 57 Australia PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 58 Australia PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 59 Thailand PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 60 Thailand PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 61 Thailand PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 62 Latin America PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 63 Latin America PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 64 Latin America PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 65 Brazil PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 66 Brazil PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 67 Brazil PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 68 Mexico PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 69 Mexico PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 70 Mexico PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 71 Argentina PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 72 Argentina PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 73 Argentina PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 74 MEA PARP inhibitor biomarkers market, by region, 2018 - 2030 (USD Million)
Table 75 MEA PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 76 MEA PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 77 MEA PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 78 South Africa PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 79 South Africa PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 80 South Africa PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 81 Saudi Arabia PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 84 UAE PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 85 UAE PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 86 UAE PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
Table 87 Kuwait PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
Table 88 Kuwait PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
Table 89 Kuwait PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 PARP inhibitor biomarkers market: market outlook
Fig. 14 PARP inhibitor biomarkers competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook.
Fig. 17 Industry value chain analysis
Fig. 18 PARP inhibitor biomarkers market driver impact
Fig. 19 PARP inhibitor biomarkers market restraint impact
Fig. 20 PARP inhibitor biomarkers market strategic initiatives analysis
Fig. 21 PARP inhibitor biomarkers market: Product movement analysis
Fig. 22 PARP inhibitor biomarkers market: Product outlook and key takeaways
Fig. 23 Kits market estimates and forecast, 2018 - 2030
Fig. 24 Assays market estimates and forecast, 2018 - 2030
Fig. 25 PARP inhibitor biomarkers market: Services movement analysis
Fig. 26 PARP inhibitor biomarkers market: Services outlook and key takeaways
Fig. 27 BRCA 1 & 2 Testing market estimates and forecasts, 2018 - 2030
Fig. 28 HRD Testing market estimates and forecasts,2018 - 2030
Fig. 29 HRR Testing market estimates and forecasts, 2018 - 2030
Fig. 30 Others market estimates and forecasts,2018 - 2030
Fig. 31 PARP inhibitor biomarkers market: Application movement analysis
Fig. 32 PARP inhibitor biomarkers market: Application outlook and key takeaways
Fig. 33 Breast Cancer market estimates and forecasts, 2018 - 2030
Fig. 34 Ovarian Cancer market estimates and forecasts,2018 - 2030
Fig. 35 Others market estimates and forecasts, 2018 - 2030
Fig. 36 Global PARP inhibitor biomarkers market: Regional movement analysis
Fig. 37 Global PARP inhibitor biomarkers market: Regional outlook and key takeaways
Fig. 38 Global PARP inhibitor biomarkers market share and leading players
Fig. 39 North America
Fig. 40 North America market estimates and forecasts, 2018 - 2030
Fig. 41 U.S. key country dynamics
Fig. 42 U.S. market estimates and forecasts, 2018 - 2030
Fig. 43 Canada key country dynamics
Fig. 44 Canada market estimates and forecasts, 2018 - 2030
Fig. 45 Europe
Fig. 46 Europe market estimates and forecasts, 2018 - 2030
Fig. 47 UK key country dynamics
Fig. 48 UK market estimates and forecasts, 2018 - 2030
Fig. 49 Germany key country dynamics
Fig. 50 Germany market estimates and forecasts, 2018 - 2030
Fig. 51 France key country dynamics
Fig. 52 France market estimates and forecasts, 2018 - 2030
Fig. 53 Italy key country dynamics
Fig. 54 Italy market estimates and forecasts, 2018 - 2030
Fig. 55 Spain key country dynamics
Fig. 56 Spain market estimates and forecasts, 2018 - 2030
Fig. 57 Denmark key country dynamics
Fig. 58 Denmark market estimates and forecasts, 2018 - 2030
Fig. 59 Sweden key country dynamics
Fig. 60 Sweden market estimates and forecasts, 2018 - 2030
Fig. 61 Norway key country dynamics
Fig. 62 Norway market estimates and forecasts, 2018 - 2030
Fig. 63 Asia Pacific
Fig. 64 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 65 China key country dynamics
Fig. 66 China market estimates and forecasts, 2018 - 2030
Fig. 67 Japan key country dynamics
Fig. 68 Japan market estimates and forecasts, 2018 - 2030
Fig. 69 India key country dynamics
Fig. 70 India market estimates and forecasts, 2018 - 2030
Fig. 71 Thailand key country dynamics
Fig. 72 Thailand market estimates and forecasts, 2018 - 2030
Fig. 73 South Korea key country dynamics
Fig. 74 South Korea market estimates and forecasts, 2018 - 2030
Fig. 75 Australia key country dynamics
Fig. 76 Australia market estimates and forecasts, 2018 - 2030
Fig. 77 Latin America
Fig. 78 Latin America market estimates and forecasts, 2018 - 2030
Fig. 79 Brazil key country dynamics
Fig. 80 Brazil market estimates and forecasts, 2018 - 2030
Fig. 81 Mexico key country dynamics
Fig. 82 Mexico market estimates and forecasts, 2018 - 2030
Fig. 83 Argentina key country dynamics
Fig. 84 Argentina market estimates and forecasts, 2018 - 2030
Fig. 85 Middle East and Africa
Fig. 86 Middle East and Africa market estimates and forecasts, 2018 - 2030
Fig. 87 South Africa key country dynamics
Fig. 88 South Africa market estimates and forecasts, 2018 - 2030
Fig. 89 Saudi Arabia key country dynamics
Fig. 90 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 91 UAE key country dynamics
Fig. 92 UAE market estimates and forecasts, 2018 - 2030
Fig. 93 Kuwait key country dynamics
Fig. 94 Kuwait market estimates and forecasts, 2018 - 2030
Fig. 95 Market share of key market players - PARP inhibitor biomarkers market

Companies Mentioned

  • Myriad Genetics, Inc.
  • Ambry Genetics
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • CENTOGENE N.V.
  • Amoy Diagnostics Co., Ltd.
  • Invitae Corporation
  • NeoGenomics Laboratories.
  • QIAGEN
  • Agilent Technologies, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedApril 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 904.1 Million
Forecasted Market Value ( USD ) by 2030 $ 1602.1 Million
Compound Annual Growth Rate8.5%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

PARP Inhibitor Biomarkers Market Size, Share & Trends Analysis Report By Product (Kits, and Assays), By Application, By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others), By Regional Outlook and Forecast, 2024 - 2031 - Product Image

PARP Inhibitor Biomarkers Market Size, Share & Trends Analysis Report By Product (Kits, and Assays), By Application, By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others), By Regional Outlook and Forecast, 2024 - 2031

  • Report
  • Global
From
PARP Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 - Product Image

PARP Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034

  • Report
  • 120 Pages
  • Global
From
PARP Inhibitors Drug Therapy Market by Drug, Indication, Distribution Channel - Global Forecast 2025-2030 - Product Image

PARP Inhibitors Drug Therapy Market by Drug, Indication, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2024 - Product Image

Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2024

  • Report
  • 175 Pages
  • Global
From
PARP Inhibitor Market - Product Image

PARP Inhibitor Market

  • Report
  • 200 Pages
  • Global
From

About the PARP Inhibitor Biomarkers Market

In the field of oncology, PARP inhibitors have emerged as a notable class of targeted cancer therapy, particularly for patients with specific biomarker characteristics. These drugs target poly (ADP-ribose) polymerase (PARP), an enzyme that plays a crucial role in the DNA damage repair process in cells. The effectiveness of PARP inhibitors is often linked to the presence of biomarkers such as BRCA1 and BRCA2 mutations, which are indicative of deficiencies in the homologous recombination DNA repair pathway. As a result, the development of PARP inhibitor biomarkers has become integral for the personalized treatment of various cancers, including ovarian, breast, and prostate cancers. Biomarker testing allows for the identification of patients likely to benefit from PARP inhibition, making it an important aspect of precision medicine. The market for PARP inhibitor biomarkers consists of products and services related to the identification, validation, and utilization of these biomarkers in clinical practice. Leading companies in the PARP inhibitor biomarkers market include AstraZeneca, with Lynparza (olaparib); GlaxoSmithKline, which offers Zejula (niraparib); Pfizer's Talzenna (talazoparib); and Clovis Oncology, which markets Rubraca (rucaparib). These companies are at the forefront of innovation in this therapeutic area, continually researching and developing novel biomarker-driven therapies to improve patient care in oncology. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.